Myelodysplastic syndromes (MDSs) represent hematological disorders characterized by ineffective hematopoiesis and increased risk of acute myeloid leukemia (AML).
Luspatercept treatment affects immune-regulatory subsets in patients with MDS with ring sideroblasts
Antonio Vassallo;Giuseppe Terrazzano;Flavia Carriero;Valentina Rubino
2025-01-01
Abstract
Myelodysplastic syndromes (MDSs) represent hematological disorders characterized by ineffective hematopoiesis and increased risk of acute myeloid leukemia (AML).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2950328025001050-main.pdf
accesso aperto
Tipologia:
Pdf editoriale
Licenza:
Dominio pubblico
Dimensione
277.26 kB
Formato
Adobe PDF
|
277.26 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
